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 Abstract
Background: Glassy cell carcinoma of the uterine cervix is a rare neoplasm, first described by Gluksman and 
Cherry in 1956. It is a poorly differentiated adenosquamous carcinoma, comprising about 1-2% of all cervical 
cancers. 
Case presentation: We report a case of glassy cell carcinoma of the uterine cervix in 67-year old female, nullipara, 
diagnosed two months after symptom onset, in IV-B stage of the disease according to the FIGO classification 
scale. Cervical smear test obtained three years previously was normal. She was offered a palliative antihemorrhagic 
radiotherapy of the pelvis and palliative chemotherapy with paclitaxel-carboplatin combination. The patient died 
within six months of diagnosis. 
Conclusions: We present a case of a rare carcinoma of the uterine cervix  with quick progression and poor 
outcome.
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Introduction
Glassy	 cell	 carcinoma	 was	 first	 described	 in	 1956	 by	
Gluksman	and	Cherry.	It	was	classified	as	a	poorly	differentiated	
cancer,	with	features	of	squamous	as	well	as	glandular	structures	
[1].	It	 is	a	rare	neoplasm,	comprising	only	1-2%	of	all	cervical	
cancers,	with	 an	 aggressive	 course	with	quick	progression	 and	
resistance	to	radiotherapy	[2,	3,14,	18].	
The	prognosis	 is	poor.	Therapy	outcomes	are	similar	as	 in	
cervical	adenocarcinoma	only	in	very	early	clinical	stages	and	on	
condition	that	radical	surgery		is	possible	[3].	
We	present	a	case	report	of	a	female	diagnosed	with	a	glassy	
cell	carcinoma.
Case report
A	 67-year-old	 patient	 J.T.K.	 was	 admitted	 to	 the	 1st 
Department	 of	Obstetrics	 and	Gynecology,	Medical	University	
of	Warsaw,	in	January	2010	due	to	recurrent	vaginal	bleeding.	
In	anamnesis:	menarche	at	the	age	of	15,	last	menstruation	at	
the	age	of	46,	nullipara.	In	1990	she	was	diagnosed	with	phyllodes	
tumor	of	the	left	breast	and	underwent	Patey’s	mastectomy.	Two	
months	prior	she	had	noticed	three	episodes	of	vaginal	bleeding	
and	 complained	 of	 urinary	 urgency	 and	 frequent	 urination.	
Cervical	smear	performed	in	November	2009	revealed	presence	
of	carcinomatous	cells	whereas	 the	results	of	 the	previous	 test,	
three	years	before,	had	been	normal.	On	admission	she	was	 in	
good	general	condition.	The	speculum	examination	revealed	an	
exophytic	tumor	(4x2cm)	of	the	cervix	infiltrating	the	posterior	
vaginal	 fornix.	 The	 bimanual	 examination	 showed	 anteflexed,	
enlarged,	 soft	 uterus,	 with	 involvement	 of	 parametrium	 and	
enlarged	 adnexa	 bilaterally.	 Transvaginal	 ultrasound	 revealed	
heterogeneous	cervix	45	mm	in	diameter	and	anteflexed	uterus	
measuring	 69x49mm	 with	 thickened	 (15mm)	 heterogeneous	
endometrium	 and	 fluid	 collection	 (30x40mm)	 in	 the	 uterine	
cavity.	Doppler	 imaging	showed	increased	vascularization	with	
low-resistance	flow	signals.	Ultrasound	of	 the	 adnexa	 revealed	
bilaterally	 two	cystic-solid	masses	measuring	59	and	52mm	 in	
diameter.	Free	fluid	in	the	Douglas	pouch	was	also	observed.	In	
laboratory	 test	markedly	 elevated	 serum	Ca-125	 concentration	
(532U/ml)	was	found.	An	excisional	biopsy	of	the	cervical	mass	
with	simultaneous	curettage	of	cervical	canal	and	uterine	cavity	
was	performed.	
The	 histopathological	 examination	 revealed	 glassy	 cell	
carcinoma	of	the	uterine	cervix.	Figures	1-3	present	microscopic	
images	of	analyzed	specimens,	with	pathognomic	for	glassy	cell	
carcinoma	 areas	 of	 eosinophilic	 stromal	 infiltration	 among	 the	
malignant	cells.	(Figure	3).	
Imaging	 tests	 showed	metastases	 in	 the	 abdominal	 lymph	
nodes,	bones	(ribs	and	vertebral	column)	as	well	as	the	left	lung.	
The	woman	was	offered	palliative	antihemorrhagic	radiotherapy	
of	 the	 pelvis	 with	 a	 total	 dose	 of	 20	 Gy,	 radiotherapy	 of	 the	
lumbar	 spine	 L5	 area	 with	 a	 dose	 of	 800	 cGY	 and	 palliative	
chemotherapy	with	paclitaxel-carboplatin	combination.	She	died	
due	to	the	disease	in	June	2010.
Discussion
In	 the	 year	 2008	 alone,	 cervical	 cancer	 was	 diagnosed	 in	
3270	women	in	Poland,	1745	of	who	died	due	to	the	disease	[7].	
Such	high	mortality	rates	place	Poland	at	one	of	the	last	places	in	
the	European	cancer	statistics.	In	order	to	improve	the	situation,	a	
Population-based	Program	of	Prophylaxis	and	Early	Detection	of	
Cervical	Cancer	has	been	introduced		since	2006,	in	accordance	
with	European	and	WHO	Guidelines	[8].	Although	the	number	
of	participants	has	been	constantly	rising	(21.15%	of	the	covered	
population	 in	 2007,	 24,39%	 in	 2008,	 26.77%	 in	 2009),	 the	
percentage	 of	 screened	 population	 remains	 significantly	 lower	
than	in	other	European	countries	[8].	
The	 pathological	 criteria	 of	 glassy	 cell	 carcinoma	 of	 the	
uterine	 cervix	were	 described	 for	 the	 first	 time	 by	Gluksmann	
and	Cherry	in	1956,	with	further	modification	by	Littman	in	1976	
[3,	4].	The	characteristic	features	of	the	malignant	cells	include:	
large	 amount	 of	 cytoplasm	 with	 ground-glass	 appearance,	
distinct	 cell	 membranes	 and	 large	 nuclei	 with	 prominent	
nucleoli.	Gluksmann	and	Cherry	classified	glassy	cell	carcinoma	
as	the	least	differentiated	form	of	adenosquamous	cancer	of	the	
uterine	 cervix.	 The	 WHO	 classification	 considers	 glassy	 cell	
carcinoma	 as	 a	 subgroup	 of	 other	 non-epithelial	 malignancies	
(adenosquamous	carcinoma)	[6].	Mean	age	at	diagnosis	reported	
in	the	literature	is	35-42	years	[2,	3,	11,	12,	14],	which	is	10	years	
earlier	than	in	other	histological	subtypes	of	cervical	carcinomas.	
The	oncologists	emphasize	higher	prevalence	of	this	malignancy	
in	multiparas	[12],	and	some	authors	suggest	its	coincidence	with	
pregnancy	[1,	3,	5].	
 Streszczenie  
Wprowadzenie: Glassy cell carcinoma szyjki macicy jest rzadkim nowotworem, po raz pierwszy opisanym przez 
Gluksmana i Cherry’ego w 1956 roku, stanowiącym około 1-2 % wszystkich raków szyjki macicy. Jest to nowotwór 
niskozróżnicowany, wykazujący cechy zarówno struktur gruczołowych, jak i płaskonabłonkowych. 
Opis przypadku: U 67-letniej kobiety, nieródki, dwa miesiące po pojawieniu się pierwszych objawów, zdiagnozo-
wano glassy cell carcinoma szyjki macicy w stopniu IV-B według FIGO. Wynik poprzedniej cytologii pobranej przed 
trzema laty był prawidłowy. Pacjentkę poddano paliatywnej radioterapii miednicy mniejszej oraz chemioterapii dwu-
lekowej palitakselem i karboplatyną. Chora zmarła w ciągu 6 miesięcy od rozpoznania choroby.
Wniosek: Przedstawiony przypadek prezentuje gwałtowny przebieg i złe rokowanie charakterystyczne dla tego 
rzadkiego nowotworu.
 Słowa kluczowe: glassy cell carcinoma / rak szyjki macicy / 
      / rak gruczołowo-płaskonabłonkowy /   
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Our	patient	was	a	nullipara,	25	years	older	than	the	mean	age	
at	diagnosis	reported	in	the	literature,	and	she	was	diagnosed	with	
the	late-stage	disease	(FIGO	IVB).	Usually	an	abnormal	vaginal	
bleeding,	often	contact	postcoital	bleeding,	is	the	first	symptom	
indicating	the	presence	of	glassy	cell	carcinoma	[2,	12,	18].	
The	 median	 time	 between	 the	 onset	 of	 symptoms	 and	
diagnosis	 is	 3	months	 [12,	 18].	The	malignancy	 is	most	 often	
diagnosed	in	FIGO	IB	stage.	In	one	third	of	the	affected	women	
the	cervical	cytology	smear	performed	in	the	previous	two	years	
is	normal	[12].	
Our	patient	had	a	normal	Pap	test	three	years	earlier,	and	the	
one	performed	on	the	occurrence	of	symptoms	revealed	malignant	
cells.	The	time	elapsed	from	onset	of	symptoms	to	diagnosis	was	
three	months.	Glassy	cell	carcinoma	is	usually	characterized	by	
an	exophytic	growth,	endophytic	tumors	in	form	of	barrel-shaped	
cervix	are	found	less	frequently.	It	has	a	rapid	growth	pattern	with	
metastases	into	lymph	nodes	and	distant	organs	[1,	2].	Metastases	
are	mainly	observed	in	lungs,	liver,	spleen	and	bone	marrow.	In	
our	patient	at	the	time	of	diagnosis	metastases	were	found	in	lungs	
and	bones.	Available	treatment	options	depend	on	clinical	staging	
and	may	include	surgery,	radio-	and	chemotherapy	(similarly	as	
in	 squamous	cell	 carcinoma	or	adenocarcinomas	of	 the	uterine	
cervix),	 but	 the	 prognosis	 is	 poor	 [6].	 5-year	 survival	 rates	 of	
patients	with	stage	I	glassy	cell	carcinoma	are	55-65%	[11,	12],	
and	for	all	stages	only	13-30%	[18].	
Radical	 hysterectomy	 followed	by	 radiation	 therapy	 is	 the	
treatment	of	choice	for	patients	with	stage	I	glassy	cell	carcinoma.	
Nasu	et	al.,	and	Peters	et	al.,	reported	a	significant	improvement	
of	 5-year	 survival,	 reaching	 80%,	 when	 cisplatin-containing	
chemotherapy	 was	 administered	 [14,	 15].	 There	 are	 also	 case	
reports	available	in	the	literature,	reporting	successful	treatment	of	
glassy	cell	carcinoma	stage	IIB	and	IIIB	by	means	of	neoadjuvant	
polichemotherapy	(paclitaxel,	carboplatin,	etoposide,	epirubicin,	
mitomycin	 C)	 followed	 by	 surgery	 after	 significant	 decrease	
in	 tumor	 size	 [13,	 14].	 Widely	 used	 paclitaxel-carboplatin	
combination	is	an	effective	two-drug	regimen	[14,	16,	17].	Our	
patient	 was	 offered	 palliative	 treatment	 with	 above	mentioned	
chemotherapeutics	on	account	of	these	reports.	
Unfortunately,	 glassy	 cell	 carcinoma	 of	 the	 uterine	 cervix	
is	 relatively	 often	 diagnosed	 in	 women	 of	 reproductive	 age.	
Therefore,	 the	 need	 of	 conservative	 treatment	 may	 have	
to	 be	 considered.	 Trachelectomy	 with	 laparoscopic	 pelvic	
lymphadenectomy	is	increasingly	more	often	offered	to	patients	
with	early	stages	of	cervical	cancer.	Plante	reported	successful	use	
of	this	method	in	cases	of	glassy	cell	carcinoma	[9].	Ferrandina	et	
al.,	reported	a	case	of	conservative	treatment	with	conisation	and	
laparoscopic	lymphadenectomy	in	a	female	diagnosed	with	stage	
IB1	glassy	cell	carcinoma	[10].	During	3-year	follow-up	no	signs	
of	recurrence	were	noted.	
Establishing	clinical	guidelines	for	the	glassy	cell	carcinoma	
management	depending	on	clinical	stage	is	difficult	due	to	low	
prevalence	of	this	malignancy	in	general	population.	Treatment	
option	is	often	selected	on	the	basis	of	thorough	analysis	of	the	
individual	case,	as	well	as	the	reports	from	the	literature.
Figure 1.  Groups of carcinoma clear cells separated with connective tissue 
fibers.    
Figure 2.  Carcinoma cells create  quasi glandular ducts.    
Figure 3.  Areas of eosinophilic stromal infiltration among the malignant cells  
– a pathognomic symptom for glassy cell carcinoma..    
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Conclusion
Glassy	 cell	 carcinoma	 is	 a	 rare	 neoplasm	 of	 the	 uterine	
cervix.	Our	case	report	confirms	its	aggressive	course	and	rapid	
progression:	onset	of	clinical	symptoms	only	two	months	before	
the	diagnosis	of	late-stage	carcinoma	and	eventual	demise	of	our	
patient	within	6	months.
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